PROVIGIL Drug Patent Profile
✉ Email this page to a colleague
When do Provigil patents expire, and what generic alternatives are available?
Provigil is a drug marketed by Cephalon and is included in one NDA. There is one patent protecting this drug.
This drug has sixty-two patent family members in twenty-eight countries.
The generic ingredient in PROVIGIL is modafinil. There are twenty-six drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the modafinil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Provigil
A generic version of PROVIGIL was approved as modafinil by ORBION PHARMS on September 26th, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PROVIGIL?
- What are the global sales for PROVIGIL?
- What is Average Wholesale Price for PROVIGIL?
Summary for PROVIGIL
| International Patents: | 62 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 70 |
| Patent Applications: | 4,417 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for PROVIGIL |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PROVIGIL |
| What excipients (inactive ingredients) are in PROVIGIL? | PROVIGIL excipients list |
| DailyMed Link: | PROVIGIL at DailyMed |
Recent Clinical Trials for PROVIGIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Kuwait University | Early Phase 1 |
| Ottawa Hospital Research Institute | Phase 3 |
| The Ottawa Hospital | Phase 3 |
Pharmacology for PROVIGIL
| Drug Class | Sympathomimetic-like Agent |
| Physiological Effect | Central Nervous System Stimulation Increased Sympathetic Activity |
US Patents and Regulatory Information for PROVIGIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cephalon | PROVIGIL | modafinil | TABLET;ORAL | 020717-001 | Dec 24, 1998 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Cephalon | PROVIGIL | modafinil | TABLET;ORAL | 020717-002 | Dec 24, 1998 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PROVIGIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cephalon | PROVIGIL | modafinil | TABLET;ORAL | 020717-001 | Dec 24, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Cephalon | PROVIGIL | modafinil | TABLET;ORAL | 020717-002 | Dec 24, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Cephalon | PROVIGIL | modafinil | TABLET;ORAL | 020717-001 | Dec 24, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Cephalon | PROVIGIL | modafinil | TABLET;ORAL | 020717-002 | Dec 24, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Cephalon | PROVIGIL | modafinil | TABLET;ORAL | 020717-001 | Dec 24, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Cephalon | PROVIGIL | modafinil | TABLET;ORAL | 020717-001 | Dec 24, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PROVIGIL
See the table below for patents covering PROVIGIL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2002318155 | ⤷ Sign Up | |
| Bulgaria | 62952 | ⤷ Sign Up | |
| Canada | 1091679 | PROCEDE DE PREPARATION DE DERIVES D'ACETAMIDES UTILES NOTAMMENT EN THERAPEUTIQUE (PREPARATION PROCESS OF ACETAMIDE DERIVATIVES WITH THERAPEUTICAL USES) | ⤷ Sign Up |
| Spain | 2325860 | ⤷ Sign Up | |
| Taiwan | 200500097 | ⤷ Sign Up | |
| European Patent Office | 0233106 | (-)-BENZHYDRYLSULFINYLACETAMIDE, PROCESS FOR ITS PREPARATION AND ITS USE IN THERAPY | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
